Citi upgraded Mirati Therapeutics to Buy from Neutral with a price target of $48, down from $51. The analyst believes Mirati’s decision to reinstate its former CEO and founder as interim CEO “is a prudent one.” Even with yesterday’s 30% rally, the company’s valuation remains depressed relative to late-2022 levels, the analyst tells investors in a research note. The firm expects the story “will begin to evolve beyond G12C” over the next 12 months given multiple readouts planned for earlier stage programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics: Cancer Discovery publishes results from MRTX1719 trial
- UPS downgraded, Eli Lilly upgraded: Wall Street’s top analyst calls
- Mirati Therapeutics trading resumes
- Mirati Therapeutics trading halted, volatility trading pause
- Mirati Therapeutics price target lowered to $31 from $40 at BMO Capital